Financings - Articles - Page 107

Neurology/Psychiatric

Curasen receives investment to advance α1A-AR agonist for Alzheimer’s disease

Oct. 10, 2023

Curasen Therapeutics Inc. has received a strategic investment of up to $5.8 million from the Alzheimer’s Drug Discovery Foundation (ADDF) to advance CST-3056, an α1A-adrenoceptor (α1A-AR) agonist for the treatment of Alzheimer’s disease.

Financings for Oct. 9, 2023

Oct. 9, 2023

No Comments

Med-tech firms raising money in public or private financings, including: Pixelgen.

Med-tech financings September 2023

Med-tech companies raise $646M in September, down 44% through Q3

Oct. 9, 2023

By Amanda Lanier

No Comments

Through the third quarter 2023 med-tech firms raised $14.35 billion in financings, down 43.82% from $25.55 billion raised in the same period last year. Money raised is also down from $42.04 billion raised in 2021, $47.61 billion in 2020 and $29.66 billion in the first nine months of 2019.

Ernst & Young: Sky-high med-tech valuations nose-dived in 2022, remain grounded in 2023

Oct. 9, 2023

By Annette Boyle

No Comments

Management teams beset by angry activist investors may take some solace in Ernst & Young (EY)’s latest Pulse of the Industry report, which confirms what med-tech executives have said for the better part of two years. A post-COVID-19 slump combined with inflation and other unfavorable capital conditions have slammed the global med-tech industry back to earth with little likelihood of a return to the halcyon days of 2021 any time soon.

Financings for Oct. 9, 2023

Oct. 9, 2023

No Comments

Biopharmas raising money in public or private financings, including: Astronautx, GSK, Limmatech.

Biopharma financings September 2023

Value of biopharma financings in September the highest in 2023

Oct. 6, 2023

By Amanda Lanier

No Comments

Through September 2023, biopharmas raised a total of $49.15 billion, up 7.46% in value from the $45.74 billion raised in the same period last year. Value is down from $93.98 billion raised in 2021 and $104.09 billion in 2020, but up from $42.17 billion raised in 2019 in the same time period.

Biopharma financings September 2023

Value of biopharma financings in September the highest in 2023

Oct. 6, 2023

By Amanda Lanier

No Comments

Through September 2023, biopharmas raised a total of $49.15 billion, up 7.46% in value from the $45.74 billion raised in the same period last year. Value is down from $93.98 billion raised in 2021 and $104.09 billion in 2020, but up from $42.17 billion raised in 2019 in the same time period.

BioFuture 2023: Sowing the seeds of pharma

Oct. 6, 2023

By Lee Landenberger

No Comments

To get ahead in a tough market like the industry now finds itself, companies are advised to know themselves and their business well, better than they probably think they know themselves. A panel of investors at the BioFuture 2023 conference cautioned that CEOs must have a deep understanding of how their companies are differentiated from their competition in order to thrive.